4D Molecular Therapeutics, Inc.

FDMT

NASDAQ

Healthcare

Biotechnology

EmeryVille, CA, US227 employees4dmoleculartherapeutics.com

$9.49

-0.38(-3.85%)

Mkt Cap $484M

$2.51

$12.27

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Collaboration And License Revenue (100%).

8-K

On March 25, 2026, 4D Molecular Therapeutics appointed Kristian Humer as Principal Accounting Officer, succeeding Ashoo Gupta, who continues as Vice President, Finance and Controller.

$484M

Market Cap

$75M

Revenue

-$123M

Net Income

Employees227

Fundamentals

How The Business Makes Money

Revenue by Segment

Collaboration And License Revenue100%($42M)

Revenue by Geography

US97.3%($20M)

NL2.7%($567.0K)

Activity

What Changed Recently

Management Change

Mar 29, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25,

Securities Issuance

Jan 25, 2026

Unregistered Sales of Equity Securities. Issuance of Pre-Funded Warrants in Exchange for Common Stock On January 22, 2026, 4D Molecular Therapeutics, Inc. (the

Financial Results

Jan 6, 2026

Results of Operations and Financial Condition. As of December 31, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) estimates that it had approximately $514

Peer Companies

Company	Price	Change	Market Cap	P/E
KALVKalVista Pharmaceuticals,...	$19.91	+0.68%	$1.0B	-4.3
OMEROmeros Corporation	$10.94	-9.44%	$776M	-5.8
CMPXCompass Therapeutics, Inc...	$5.46	+0.55%	$755M	-14.0
LXRXLexicon Pharmaceuticals, ...	$1.59	-2.74%	$676M	-11.8
PRTAProthena Corporation plc	$9.82	-2.09%	$529M	-1.9
ADCTADC Therapeutics S.A.	$3.80	+0.03%	$483M	-4.3
RGNXREGENXBIO Inc.	$8.52	-1.27%	$440M	-2.2
BCYCBicycle Therapeutics plc	$5.06	+3.27%	$350M	-1.4

Analyst View

Company Profile

CIK0001650648

ISINUS35104E1001

CUSIP35104E100

Phone510 505 2680

Address5858 Horton Street, EmeryVille, CA, 94608, US

SEC EDGAR